Juvena Therapeutics’ Post

Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034: Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim … Continue reading → #PharmaceuticalsBiotech

🧐Title: "Stimuli-responsive hydrogel actuators for skin therapeutics and beyond" This paper first categorizes the types of external stimuli that hydrogel actuators respond to and outlines their applications in skin therapeutics. It then reviews therapeutic potentials of hydrogel actuators beyond the skin, and discusses the challenges and future prospects for the development of stimuli-responsive hydrogel actuators. 🔗Full text: https://lnkd.in/ghrdyzRd #Hydrogelactuators #drugdelivery

Today we announced groundbreaking enzymatic synthesis data at the #TIDESUSA annual meeting! Codexis has successfully synthesized a full-length, known siRNA oligonucleotide from starting material through the attachment of a conjugation moiety via an enzymatic route to support RNA-based therapeutics manufacturing. RNAi therapeutics key opinion leader John Maraganore noted, “The data presented today by Codexis are truly unprecedented—I believe this is the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety. This milestone provides meaningful proof of process to industry that there are alternative manufacturing methods available as the demand for RNAi therapeutics increases. The ECO Synthesis™ manufacturing platform has the potential to be a scalable and sustainable way to manufacture this important and growing new class of medicines.” Read our press release for more information: https://lnkd.in/d9WquAUY #enzymeengineering #proteinengineering #RNAi #RNAimanufacturing #enzymaticsynthesis

Interested in learning more about icIEF fractionation followed by mass spec? We have a webinar next week, on June 20th, with Lan Li from Amgen and Amreen Jonas from Mersana Therapeutics. You can use the link below to register. I am very excited about this one! #MassSpec

Interesting Study! What if unresectable stage 3 NSCLC patients could be converted to resectable status through neoadjuvant Chemo-IO? In patients with unresectable stage 3 NSCLC, neoadjuvant therapy with SHR-1701 (anti-PD-L1/TGF-βRII) and chemotherapy led to surgery in 25% of patients, with half of these surgeries performed minimally invasively. Post-surgery, the pCR was 26%, and the 18-month EFS was 74.1%. Ref: https://lnkd.in/gBgKBPGF

𝐍𝐞𝐰𝐬 𝐚𝐛𝐨𝐮𝐭 𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Personalize medicine based on peptide has made great progress in recent years. As more and more clinical projects were initiated the demand for small scale GMP grade peptides was also picking up quickly. Hence, Intavis Peptide Services decided in 2019 to build 𝐚 𝐆𝐌𝐏 𝐀𝐏𝐈 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲. Lo and behold, we are on schedule and eagerly await the opening ceremonies planned for Q4 of 2024. If you are you planning any 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐨𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, don’t hesitate to check out 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞. #gmp #drugdevelopment #peptides #clinicaltrials #intavis

🚀 Kicking off Day 2 of the 20th BioPharma Drug Discovery Nexus Conference with a bang! Join Mauro Mileni Founder and CEO, Abilita Therapeutics, Inc. as he unveils insights into 'Enabling the Discovery of Therapeutic Antibodies Targeting Challenging Membrane Proteins'. Don't miss out on this enlightening session! #BioPharma #DrugDiscovery #Innovation #Antibodies #Therapeutics #Membraneproteins #Epitopes #Conformational #Protiens #NexusConference #SanDiego #USconference #ScientificConference

In our latest technical brief, we examine backbone modifications within nucleic acids. From L-DNA monomers to 2′-5′-linkages, delve into some of the non-natural backbone modifications shaping the landscape of nucleic acid therapeutics. Discover how altering the phosphate backbone can have an effect on drug design, enhance resistance to nucleases, and unlock therapeutic possibilities. 📖 Read the full article here: https://bit.ly/4bhritP

We are pleased to share an important development from our portfolio company, Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs). Confo Therapeutics has announced the publication of groundbreaking research in Nature Communications, presenting the world’s first structure of a complex between an antibody-based agonist and a Class A GPCR. This achievement specifically focuses on the melanocortin receptor 4 (MC4R), a critical component of the melanocortin receptor family and a key regulator in the leptin-melanocortin molecular axis, which governs hunger and satiety. This significant advancement underscores Confo’s ongoing commitment to pioneering new therapeutic pathways in the treatment of diseases involving GPCRs. Click on the following link to learn more: https://lnkd.in/ehckZdp4 #BGV #ConfoTherapeutics #GPCRResearch #LifeSciencesInnovation #ObesityResearch #lifesciences #biotech Edward Van Wezel Diede Brunen

Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar: The global GEP-NET therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research...